Literature DB >> 21674124

Pharmacological inhibition of the Hedgehog pathway prevents human rhabdomyosarcoma cell growth.

Naoya Kawabata1, Kosei Ijiri, Yasuhiro Ishidou, Takuya Yamamoto, Hiroko Nagao, Satoshi Nagano, Shingo Maeda, Setsuro Komiya, Takao Setoguchi.   

Abstract

The Hedgehog pathway functions as an organizer in embryonic development. Recent studies have shown that mutation of the PTCH1 gene involved in the Hedgehog pathway affects rhabdomyosarcoma development. However, the expression of Hedgehog pathway molecules in human rhabdomyosarcoma cells has not been well clarified. In addition, the effect of pharmacological inhibition of the Hedgehog pathway is not known. We investigated the expression of the genes involved in the Hedgehog pathway using human rhabdomyosarcoma cell lines and biopsy specimens. Further, we evaluated the effect of pharmacological inhibition of the Hedgehog pathway using cyclopamine or GANT61 by WST assay, cell proliferation assay and cell death detection assay. Real-time PCR revealed that human rhabdomyosarcoma cell lines and biopsy specimens overexpressed the following genes: Sonic hedgehog, Indian hedgehog, Desert hedgehog, PTCH1, SMO, GLI1, GLI2 and ULK3. Immunohistochemistry revealed that rhabdomyosarcoma cell lines and biopsy specimens expressed SMO and GLI2. Inhibition of SMO by cyclopamine slowed the growth of human rhabdomyosarcoma cell lines. Similarly, inhibition of GLI by GANT61 slowed the growth of human rhabdomyosarcoma cell lines. Inhibition of cell proliferation and apoptotic cell death together prevented the growth of rhabdomyosarcoma cells by cyclopamine and GANT61 treatment. Our findings suggest that pharmacological inhibition of the Hedgehog pathway may be a useful approach for treating rhabdomyosarcoma patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674124     DOI: 10.3892/ijo.2011.1076

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

1.  Primary cilia control hedgehog signaling during muscle differentiation and are deregulated in rhabdomyosarcoma.

Authors:  Wenxiang Fu; Patrik Asp; Brian Canter; Brian David Dynlacht
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

2.  Hedgehog signaling pathway and ovarian cancer.

Authors:  Qi Chen; Guolan Gao; Shiwen Luo
Journal:  Chin J Cancer Res       Date:  2013-06       Impact factor: 5.087

3.  FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.

Authors:  Masaaki Kuda; Kenichi Kohashi; Yuichi Yamada; Akira Maekawa; Yoshiaki Kinoshita; Tetsuya Nakatsura; Yukihide Iwamoto; Tomoaki Taguchi; Yoshinao Oda
Journal:  Tumour Biol       Date:  2015-11-09

4.  Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis.

Authors:  Chuan Bian Lim; Cecilia M Prêle; Svetlana Baltic; Peter G Arthur; Jenette Creaney; D Neil Watkins; Philip J Thompson; Steven E Mutsaers
Journal:  Oncotarget       Date:  2015-01-30

5.  GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis.

Authors:  Ritesh K Srivastava; Samer Zaid Kaylani; Nayf Edrees; Changzhao Li; Sarang S Talwelkar; Jianmin Xu; Komaraiah Palle; Joseph G Pressey; Mohammad Athar
Journal:  Oncotarget       Date:  2014-12-15

6.  Up-regulation of GLI1 in vincristine-resistant rhabdomyosarcoma and Ewing sarcoma.

Authors:  Joon Won Yoon; Marilyn Lamm; Christopher Chandler; Philip Iannaccone; David Walterhouse
Journal:  BMC Cancer       Date:  2020-06-03       Impact factor: 4.430

7.  Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model.

Authors:  Natalia Garcia; Mara Ulin; Mohamed Ali; Ayman Al-Hendy; Katia Candido Carvalho; Qiwei Yang
Journal:  Reprod Sci       Date:  2021-10-12       Impact factor: 3.060

8.  RBPJ is a novel target for rhabdomyosarcoma therapy.

Authors:  Hiroko Nagao; Takao Setoguchi; Sho Kitamoto; Yasuhiro Ishidou; Satoshi Nagano; Masahiro Yokouchi; Masahiko Abematsu; Naoya Kawabata; Shingo Maeda; Suguru Yonezawa; Setsuro Komiya
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

9.  Survivin-responsive conditionally replicating adenovirus kills rhabdomyosarcoma stem cells more efficiently than their progeny.

Authors:  Kiyonori Tanoue; Yuqing Wang; Minako Ikeda; Kaoru Mitsui; Rie Irie; Takao Setoguchi; Setsuro Komiya; Shoji Natsugoe; Ken-Ichiro Kosai
Journal:  J Transl Med       Date:  2014-01-27       Impact factor: 5.531

10.  Weight loss reduces basal-like breast cancer through kinome reprogramming.

Authors:  Yuanyuan Qin; Sneha Sundaram; Luma Essaid; Xin Chen; Samantha M Miller; Feng Yan; David B Darr; Joseph A Galanko; Stephanie A Montgomery; Michael B Major; Gary L Johnson; Melissa A Troester; Liza Makowski
Journal:  Cancer Cell Int       Date:  2016-04-01       Impact factor: 5.722

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.